Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Vladimir Putin annexes four Ukrainian regions
    • Russia withdraws from key eastern city of Lyman as Ukrainians advance
    • Military briefing: Ukraine forces close to encircling Russian troops in key town
    • Lael Brainard signals Fed concern over emerging market vulnerabilities
    • Europe increases defence of energy assets after Baltic Sea ‘sabotage’
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Inside the breakdown of the UK’s mortgage machine
      • Prestigious Hong Kong flats stand empty as property market slumps
      • Elon Musk unveils Tesla’s humanoid robot prototype
      • McKinsey charged over role in South Africa’s ‘state capture’ scandal
      • BlackRock threatened to halt trading at height of UK market tumult
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Seven days that shook the UK
      • UK watchdogs hold crisis talks to avert gilts cliff-edge
      • UK pension funds sell assets and tap employers in rush for cash
      • US stocks record longest run of quarterly declines since 2008 crisis
      • Sterling almost erases losses from Kwasi Kwarteng’s mini-Budget
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • For a fascist revival look to Moscow, not Rome
      • Outlier Britain needs a credible economic plan in a hurry
      • The ‘chip choke’ on China may breathe air into semiconductor industry
      • Kwasi Kwarteng crashes the bond market love-in
      • The week that wrecked our personal finances
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Carlo Rovelli: ‘Science is not just about writing equations. It’s about reconceptualising the world’
      • Mars’ outgoing CEO on succession, family businesses and eating his own dog food
      • Talent wars: why businesses have to battle to hire the best
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything must go – Pharrell Williams is selling off his legacy
      • Hong Kong’s expat party continues — but for how long?
      • Katherine Rundell: ‘Larger than the world’s chaos are its miracles’
      • The art and science of picking winning teams
      • Summer is over. But the UK is unprepared for the heatwaves to come
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Jamie Smyth

    US Pharmaceutical Correspondent

    Jamie Smyth is the US pharmaceutical correspondent of the Financial Times. He is based in the New York bureau and covers the pharma and biotech sectors, drug discovery and healthcare issues such as the opioids crisis. He was previously Australia correspondent and Ireland correspondent.

    Before joining the FT Jamie worked as European correspondent for The Irish Times. He has a master’s degree in journalism from Dublin City University and a bachelor’s degree in history from Trinity College Dublin.

    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)
    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 28 September, 2022
      Pharmaceuticals sector
      Biogen and Eisai shares surge after Alzheimer’s drug trial success

      Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

    • Wednesday, 28 September, 2022
      Behind the Money podcast18 min listen
      Who will pay for the next Covid vaccines?

      Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic

    • Friday, 23 September, 2022
      Health sector
      Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

      Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

    • Monday, 19 September, 2022
      Covid-19 vaccines
      Investors ditch vaccine stocks after Biden says ‘pandemic is over’

      Top jab makers lose combined $10bn of market value amid fears over growing public apathy

    • Sunday, 18 September, 2022
      Covid-19 vaccines
      Fauci warns Covid politics could harm childhood vaccination efforts

      Chief US medical adviser says anti-vax attitudes could spill over and cause disease outbreaks

    • Thursday, 15 September, 2022
      Coronavirus treatment
      Biden’s Covid-19 tsar warns millions risk losing access to treatment

      Ashish Jha says vaccines and drugs will be limited if Congress fails to approve further funding

    • Tuesday, 13 September, 2022
      Coronavirus pandemic
      At least 17mn people in Europe have had long Covid, says WHO

      Women twice as likely as men to suffer condition associated with cognitive problems and fatigue, modelling shows

    • Monday, 12 September, 2022
      Covid-19 vaccines
      US criticised for rolling out Covid boosters without human trials

      Some health experts say vaccination campaign risks undermining public trust

    • Sunday, 4 September, 2022
      Pharmaceuticals sector
      US lab at the centre of legal fight over Zantac and cancer

      Pharmaceutical companies have taken aim at group whose research helped spark a wave of lawsuits

    • Tuesday, 30 August, 2022
      Takeda Pharmaceutical Co Ltd
      Takeda targets global vaccine market after approval of dengue jab

      Treatment is new weapon against mosquito-borne disease that kills 20,000 people a year

    • Friday, 26 August, 2022
      3M Co
      3M loses attempt to halt thousands of earplugs lawsuits

      Bankruptcy judge says jury trials can continue in one of the largest mass torts in US history

    • Friday, 26 August, 2022
      Covid-19 vaccines
      Moderna accuses BioNTech/Pfizer of copying mRNA technology

      US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic

    • Thursday, 25 August, 2022
      Pfizer Inc
      Pfizer races to beat rivals for slice of $10bn respiratory jab market

      US pharma group says RSV vaccine is 86% effective at preventing severe disease

    • Monday, 22 August, 2022
      Covid-19 vaccines
      Pfizer and BioNTech ask US regulator to authorise variant-specific jab

      Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials

    • Monday, 22 August, 2022
      Johnson & Johnson Co Inc
      J&J tries to extend its ‘Texas two-step’ to halt two states’ talc cases

      New Mexico and Mississippi say consumer company’s strategy is making a ‘mockery’ of bankruptcy law

    • Wednesday, 17 August, 2022
      Centers for Disease Control and Prevention
      Top US health official admits ‘dramatic mistakes’ in tackling Covid

      CDC announces shake-up to improve agency’s response to emergencies after series of mistakes

    • Sunday, 14 August, 2022
      Disease control and prevention
      Polio virus reappears in rich economies, exposing gaps in immunisation

      New York City finds evidence of long-suppressed virus linked to recent samples in UK and Israel

    • Thursday, 11 August, 2022
      Drug prices
      US poised to negotiate drug prices despite fierce pharma lobbying

      Makers of blockbuster drugs including Eli Lilly, AbbVie and AstraZeneca face new curbs

    • Monday, 8 August, 2022
      Novavax Inc
      Covid vaccine maker Novavax sinks after slashing revenue forecast

      US drugmaker’s shares fall more than 30% as it blames weak demand for jabs

    • Monday, 8 August, 2022
      Pharmaceuticals sector
      Pfizer tests vaccine to fend off spread of tick-borne Lyme disease

      US drugmaker and French partner begin late-stage trial with 14% of global population showing evidence of infection

    • Sunday, 7 August, 2022
      Pharmaceuticals sector
      Merck defends tax approach against senator’s claims of avoidance

      Chief financial officer says drugmaker complies with law amid congressional probe

    • Saturday, 6 August, 2022
      Eli Lilly & Co
      Eli Lilly says Indiana abortion ban will shift jobs out of its home state

      Pharmaceutical company says new legislation will hinder its ability to attract diverse talent

    • Friday, 5 August, 2022
      Mergers & Acquisitions
      Pfizer in talks to buy Global Blood Therapeutics for roughly $5bn

      Big Pharma group is using cash pile from sales of Covid-19 vaccines to replenish drug pipeline

    • Thursday, 4 August, 2022
      Monkeypox
      US declares public health emergency over rapid spread of monkeypox

      Decision will allow Biden administration to tap new resources to combat disease amid criticism over its response

    • Wednesday, 3 August, 2022
      Reproductive rights
      Kansas voters reject anti-abortion amendment to state constitution

      Resounding victory for pro-choice campaign in first test of public opinion after Supreme Court ruling on Roe vs Wade

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In